【Asset for Licensing】Orally bioavailable selective KIF18A small-molecule inhibitor

Asset: Orally bioavailable selective KIF18A small-molecule inhibitor
Development Stage: IND enabling stage
Indication: Multiple solid tumors
Key Asset Highlights:
（1）Exhibits high target selectivity and potent inhibitory activity against KIF18A, a novel mitotic kinesin critically involved in tumor cell division, chromosome alignment and malignant proliferation.
（2）Effectively disrupts mitotic spindle assembly and cell cycle progression, inducing robust cell cycle arrest and apoptosis in KIF18A-overexpressing solid tumor populations.
（3）Demonstrates broad-spectrum anti-tumor activity across a variety of solid tumor subtypes, showing potent in vivo tumor growth inhibition in multiple preclinical models.
（4）Possesses unique differentiated advantages over traditional cytotoxic chemotherapeutics, achieving tumor-specific mitotic interference with improved therapeutic window and reduced systemic toxicity.
（5）Features optimized oral pharmacokinetic profiles and favorable druggability, supporting flexible oral administration and further clinical transformation development.
Backed by a comprehensive global intellectual property layout, securing exclusive and stable development and commercialization rights for KIF18A-targeted solid tumor therapy.

If you are a Search & Evaluation professional working at an MNC, biopharma, biotech or VC, and are interested in this opportunity, please feel free to contact the DrugTimes BD Team.

Email: BD@drugtimes.cn

Thank you very much!

【Disclaimer】All information presented above and on this website is provided for informational purposes only. We make no guarantee as to its accuracy, completeness or timeliness. Readers shall exercise caution when referencing the content.